AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis

2020/01/13 by Joseph D. Feuerstein, Kim L. Isaacs, Yecheskel Schneider +28 · 28 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Inflammatory Bowel Disease #Microscopic Colitis #Autoimmune and Inflammatory Disorders

paper · pdf · doi:10.1053/j.gastro.2020.01.006

Citations

• Cortisone in Ulcerative Colitis

Cited by

• Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis
• Pathological mechanism and targeted drugs of ulcerative colitis: A review
• Acute severe ulcerative colitis without systemic toxicity: A retrospective multicenter cohort study suggesting refining the definition of acute severe ulcerative colitis
• Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. [europepmc]
• Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. [europepmc]
• Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. [europepmc]
• Serum biomarkers confirming stable remission in inflammatory bowel disease. [europepmc]
• Use of thiopurines in inflammatory bowel disease: an update. [europepmc]
• Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. [europepmc]
• Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. [europepmc]
• Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. [europepmc]
• Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases. [europepmc]
• Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. [europepmc]
• Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. [europepmc]
• Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. [europepmc]
• Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. [europepmc]
• Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management. [europepmc]
• JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. [europepmc]
• Is there an optimal sequence of biologic therapies for inflammatory bowel disease? [europepmc]
• Probiotics for the treatment of ulcerative colitis: a review of experimental research from 2018 to 2022. [europepmc]
• Therapeutic Antibodies in Medicine. [europepmc]
• Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource. [europepmc]
• AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders. [europepmc]
• Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial. [europepmc]
• Inflammation and aging-related disease: A transdisciplinary inflammaging framework. [europepmc]
• Ulcerative colitis: molecular insights and intervention therapy. [europepmc]
• Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. [europepmc]
• AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. [europepmc]